Multiple growth levers for Biocon; ramp-up, new biosimilars to boost profit

Ramp-up and new biosimilars should help boost profit

The Biocon stock continues to outperform its pharma peers, gaining 20 per cent since its September lows. The stock added 3 per cent to its returns on Wednesday after a decent December quarter performance, ramp-up of certain products, and fresh launches in the biologics space. The growing small molecules business, rising investments, and regulatory go-ahead for its plants are the additional triggers.

The company’s December quarter growth was led by the biologics segment, which reported a 31 per cent growth year-on-year (YoY). The segment accounts for a third of its sales. The rising sales of key biosimilars, such as Ogivri (a